Document Detail


Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation.
MedLine Citation:
PMID:  23314410     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Initiation of antiretroviral therapy during acute HIV-1 infection may prevent persistent immune activation. We analyzed longitudinal CD38+HLA-DR+ CD8+ T-cell percentages in 31 acutely infected individuals who started early (median 43 days since infection) and successful antiretroviral therapy, and maintained viral suppression through 96 weeks. Pretherapy a median of 72.6% CD8+ T cells were CD38+HLA-DR+, and although this decreased to 15.6% by 96 weeks, it remained substantially higher than seronegative controls (median 8.9%, P = 0.008). Shorter time to suppression predicted lower activation at 96 weeks. These results support the hypothesis that very early events in HIV-1 pathogenesis may result in prolonged immune dysfunction.
Authors:
Michael J Vinikoor; Anna Cope; Cynthia L Gay; Guido Ferrari; Kara S McGee; Joann D Kuruc; Jeffrey L Lennox; David M Margolis; Charles B Hicks; Joseph J Eron
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  62     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-06-13     Completed Date:  2013-10-18     Revised Date:  2014-04-28    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  505-8     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-HIV Agents / therapeutic use*
CD8-Positive T-Lymphocytes / drug effects*,  immunology*,  virology
Female
HIV Infections / blood,  drug therapy*,  immunology*,  virology
HIV-1 / isolation & purification*
Humans
Linear Models
Longitudinal Studies
Lymphocyte Activation / drug effects,  immunology
Male
Middle Aged
RNA, Viral / blood
Viral Load / immunology
Young Adult
Grant Support
ID/Acronym/Agency:
1P30 AI 50410-04/AI/NIAID NIH HHS; 1P30 AI 64518/AI/NIAID NIH HHS; 2K24 AI01608/AI/NIAID NIH HHS; 5R01 AI050483/AI/NIAID NIH HHS; 5R13 AI084562/AI/NIAID NIH HHS; 5T32 AI07001-35/AI/NIAID NIH HHS; K24 AI001608/AI/NIAID NIH HHS; P30 AI050410/AI/NIAID NIH HHS; P30 AI064518/AI/NIAID NIH HHS; R01 AI050483/AI/NIAID NIH HHS; T32 AI007001/AI/NIAID NIH HHS; UL1 TR000083/TR/NCATS NIH HHS; UL1TR000083/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/RNA, Viral
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of venous drainage in three patients with extradural spinal arteriovenous fistulae at the c...
Next Document:  HIV Infection Deregulates Tim-3 Expression on Innate Cells; Combination Antiretroviral Therapy Resul...